[go: up one dir, main page]

BR0307278A - Formulação oral de liberação imediata, e, método para preparar uma formulação - Google Patents

Formulação oral de liberação imediata, e, método para preparar uma formulação

Info

Publication number
BR0307278A
BR0307278A BR0307278-9A BR0307278A BR0307278A BR 0307278 A BR0307278 A BR 0307278A BR 0307278 A BR0307278 A BR 0307278A BR 0307278 A BR0307278 A BR 0307278A
Authority
BR
Brazil
Prior art keywords
formulation
amount
immediate release
total weight
preparing
Prior art date
Application number
BR0307278-9A
Other languages
English (en)
Inventor
Henricus R M Gorissen
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of BR0307278A publication Critical patent/BR0307278A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMULAçãO ORAL DE LIBERAçãO IMEDIATA, E, MéTODO PARA PREPARAR UMA FORMULAçãO". A presente invenção refere-se a uma formulação de liberação imediata com biodisponibilidade aumentada compreendendo uma solução homogênea e termoestável de uma substância biologicamente ativa deficientemente solúvel em água, em que a referida solução é composta de :a) a substância ativa em uma quantidade entre 10 e 50% do peso total da formulação, b) um tensoativo hidrofílico não iónico, que está na forma líquida entre 15 e 30<198>C, em uma quantidade entre 20% e 70% do peso total da formulação e c) um polimero orgânico ou mistura de polímeros orgânicos farmaceuticamente aceitável, sendo que o polímero ou mistura de polímeros está em forma líquida acima de 60<198>C e em forma sólida abaixo de 30<198>C, em uma quantidade entre 5% e 70% do peso total da formulação, e d) opcionalmente, um agente de desintegração em uma quantidade entre 1% e 10% do peso total da formulação. A invenção refere-se adicionalmente a substâncias ativas formuladas na forma acima e a métodos para produzir a formulação.
BR0307278-9A 2002-02-14 2003-02-11 Formulação oral de liberação imediata, e, método para preparar uma formulação BR0307278A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075623 2002-02-14
PCT/EP2003/050014 WO2003068266A1 (en) 2002-02-14 2003-02-11 Oral solid solution formulation of a poorly water-soluble active substance

Publications (1)

Publication Number Publication Date
BR0307278A true BR0307278A (pt) 2004-12-28

Family

ID=27619166

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307278-9A BR0307278A (pt) 2002-02-14 2003-02-11 Formulação oral de liberação imediata, e, método para preparar uma formulação

Country Status (24)

Country Link
US (2) US20050008697A1 (pt)
EP (1) EP1476196B1 (pt)
JP (1) JP2005517041A (pt)
KR (1) KR101014545B1 (pt)
CN (1) CN1273194C (pt)
AR (1) AR038681A1 (pt)
AT (1) ATE345817T1 (pt)
AU (1) AU2003208713B2 (pt)
BR (1) BR0307278A (pt)
CA (1) CA2472744A1 (pt)
DE (1) DE60309839T2 (pt)
DK (1) DK1476196T3 (pt)
ES (1) ES2277635T3 (pt)
HR (1) HRP20040613A2 (pt)
IL (2) IL162883A0 (pt)
MX (1) MXPA04007852A (pt)
NO (1) NO20043832L (pt)
PL (1) PL370452A1 (pt)
PT (1) PT1476196E (pt)
RU (1) RU2314811C2 (pt)
SI (1) SI1476196T1 (pt)
UA (1) UA79267C2 (pt)
WO (1) WO2003068266A1 (pt)
ZA (1) ZA200405608B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
TW200633713A (en) * 2004-12-23 2006-10-01 Solvay Pharm Bv Oral immediate release formulation of a poorly water-soluble active substance
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
WO2007054975A1 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2007308479A (ja) 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 固体分散体製剤
KR20090032085A (ko) * 2006-06-16 2009-03-31 솔베이 파마슈티칼스 비. 브이 수용성이 불량한 활성 물질의 경구 투여용 약제학적 조성물
JP2009541267A (ja) * 2006-06-22 2009-11-26 ソルベイ・フアーマシユーチカルズ・ベー・ブイ 低い水溶性活性物質の経口製薬学的組成物
WO2008003769A2 (en) * 2006-07-06 2008-01-10 Ares Trading S.A. An oral pharmaceutical composition of an anilinopyrimidine, its preparation and use thereof
JP2010501642A (ja) * 2006-09-01 2010-01-21 テバ ファーマシューティカル インダストリーズ リミティド カルシウム受容体−活性化合物の固体複合材料
AR071375A1 (es) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
SI2600850T1 (sl) 2010-08-04 2018-12-31 Gruenenthal Gmbh Farmacevtska oblika odmerka, ki zajema 6'-fluoro-(N-metil- ali N,N- dimetil-)-4-fenil-4',9'-dihidro-3'H-spiro(cikloheksan-1,1'-pirano (3,4,B)indol)-4-amin, za zdravljenje nociceptivne bolečine
RU2582390C2 (ru) * 2010-08-04 2016-04-27 Грюненталь Гмбх ЛЕКАРСТВЕННАЯ ДОЗИРОВАННАЯ ФОРМА, КОТОРАЯ СОДЕРЖИТ 6'-ФТОР-(N-МЕТИЛ-ИЛИ N,N-ДИМЕТИЛ-)-4-ФЕНИЛ-4', 9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН
CN107735080B (zh) * 2015-07-03 2020-10-23 浙江海正药业股份有限公司 一种人参皂苷c-k口服固体制剂及其制备方法
PL424453A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
PL424452A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
FI3886820T3 (fi) 2018-11-30 2023-05-25 Chemocentryx Inc Kapseliformulaatioita
CN121532170A (zh) * 2023-07-18 2026-02-13 三亚制药株式会社 含普仑司特的药物组合物的制备方法以及通过所述制备方法制备的药物组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3359167A (en) * 1965-07-22 1967-12-19 Pfizer & Co C Vitamin a compositions
US4325970A (en) * 1980-10-09 1982-04-20 Hoffmann-La Roche Inc. 15-Acetyl-prostaglandins
NZ224497A (en) * 1987-05-18 1990-04-26 Janssen Pharmaceutica Nv Pharmaceutical composition comprising flunarizine
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
EP0988046B1 (en) * 1997-01-30 2004-09-15 Novartis AG Oil-free pharmaceutical compositions containing cyclosporin a
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions

Also Published As

Publication number Publication date
ES2277635T3 (es) 2007-07-16
RU2004127457A (ru) 2005-04-20
UA79267C2 (en) 2007-06-11
PT1476196E (pt) 2007-02-28
ATE345817T1 (de) 2006-12-15
CA2472744A1 (en) 2003-08-21
CN1633307A (zh) 2005-06-29
DK1476196T3 (da) 2007-03-05
PL370452A1 (en) 2005-05-30
EP1476196A1 (en) 2004-11-17
JP2005517041A (ja) 2005-06-09
EP1476196B1 (en) 2006-11-22
MXPA04007852A (es) 2004-10-15
DE60309839D1 (de) 2007-01-04
KR20040085193A (ko) 2004-10-07
ZA200405608B (en) 2005-06-24
KR101014545B1 (ko) 2011-02-16
AU2003208713B9 (en) 2003-09-04
NO20043832L (no) 2004-09-13
WO2003068266A1 (en) 2003-08-21
AU2003208713B2 (en) 2007-10-18
DE60309839T2 (de) 2007-03-15
HK1077218A1 (en) 2006-02-10
CN1273194C (zh) 2006-09-06
RU2314811C2 (ru) 2008-01-20
HRP20040613A2 (en) 2005-04-30
SI1476196T1 (sl) 2007-04-30
IL162883A0 (en) 2005-11-20
IL162883A (en) 2009-05-04
US20110086844A1 (en) 2011-04-14
AU2003208713A1 (en) 2003-09-04
AR038681A1 (es) 2005-01-26
US20050008697A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
BR0307278A (pt) Formulação oral de liberação imediata, e, método para preparar uma formulação
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
BRPI0417287A (pt) espuma oleosa para uso farmacêutico e cosmético
BRPI0518101A (pt) métodos de produção e sìntese de composições nanoparticuladas, composições obtidas e seu uso
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
DE60138468D1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
PE44799A1 (es) Antagonistas del receptor de vitronectina
CA2716874A1 (en) A pharmaceutical composition and its use in the preparation of a medicament for the treatment of cerebrovascular diseases
PE20100265A1 (es) Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
NO20033564L (no) Ny formulering med modifisert frigivningsvirkning
PE20071139A1 (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
BRPI0417791A (pt) composição substancialmente anidra
AR018607A1 (es) Preparacion farmaceutica que en calidad de ingrediente activo contiene levotiroxina sodica, y un procedimiento para su preparacion
ATE253820T1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
BR0314335A (pt) Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade
PT1305057E (pt) Composicao de biomateria microparticular para uso medicinal
BRPI0513417A (pt) composição farmacêutica estável, usos de um poliol, e de uma composição, processo para preparar uma composição farmacêutica, e, método para tratar uma condição responsiva à administração de uma anti-histamina
DE602004001969D1 (de) Orale pharmazeutische Zusammensetzung und Verfahren zu ihrer Herstellung
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada
PE20050207A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros referida a enfermedades dependientes de hormonas
AR047948A1 (es) Formulaciuones de inhibidores de la fosfodiesterasa v
AR066324A1 (es) Tratamiento de endometriosis

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.